Scientific Publications: Other

• Correlation of Ex Vivo Drug Sensitivity With Clinical Response in Pediatric AML

  JCO 39, 10032-10032(2021) May. 28, 2021

• Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia

  Blood (2021) 137 (6): 751–762. Feb. 11, 2021

• Ex Vivo Drug Screening Defines Novel Drug Sensitivity Patterns for Informing Personalized Therapy in Myeloid Neoplasms

  Blood Adv (2020) 4 (12): 2768–2778 Jun. 23, 2020

• Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study

  Clin Cancer Res (2020) 26 (3): 726–737 Feb. 1, 2020

• A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

  Blood. 2019 Nov 13;134:4239. Nov. 19, 2019

• Ex Vivo Drug Sensitivity Profiling in Myelodysplastic Syndrome (Mds) Patients Defines Novel Drug Sensitivity Patterns for Predicting Clinical Therapeutic Outcomes

  HemaSphere. 2019 Jun;3:19. Jun. 30, 2019

• Molecular Pathophysiology of the Myelodysplastic Syndromes: Insights for Targeted Therapy

  Blood advances. 2018 Oct 23;2(20):2787-97. Oct. 23, 2018

• Single-Cell Mutational Profiling of Clonal Evolution in Myelodysplastic Syndromes (MDS) during Therapy and Disease Progression

  Cancer Research. 2018 Jul 1;78(13_Supplement):3004 Jul. 1, 2018

• Recurrent Drug Sensitivity Patterns in Myelodysplastic Syndrome Patients Are Recapitulated by Ex Vivo Drug Response Profiling

  Cancer Research. 2018 Jul 1;78(13_Supplement):568-. Jul. 1, 2018

• PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells

  Blood. 2017 Dec 8;130:1371. Dec. 8, 2017